Previous reports revealed that the M3 gene of both avian and mammalian reoviruses express two isoforms of the non-structural protein mNS in infected cells. The larger isoforms initiate translation at the AUG codon closest to the 59 end of their respective m3 mRNAs, and were therefore designated mNS. In this study we have performed experiments to identify the molecular mechanisms by which the smaller mNS isoforms are generated. The results of this study confirmed the previous findings indicating that the smaller mammalian reovirus mNS isoform is a primary translation product, the translation of which is initiated at the internal AUG-41 codon of mammalian reovirus m3 mRNA. Our results further revealed that the smaller avian reovirus mNS isoform originates from a specific post-translational cleavage site near the amino terminus of mNS. This cleavage produces a 55 kDa carboxy-terminal protein, termed mNSC, and a 17 kDa amino-terminal polypeptide, designated mNSN. These results allowed us to extend the known avian reovirus protein-encoding capacity to 18 proteins, 12 of which are structural proteins and six of which are non-structural proteins. Our finding that avian and mammalian reoviruses use different mechanisms to express their mNSC isoforms suggests that these isoforms are important for reovirus replication.
INTRODUCTION
Mammalian reovirus (MRV) and avian reovirus (ARV) are species groups of the genus Orthoreovirus (Chappel et al., 2005) , which differ in host range, degree of pathogenicity, genome coding capacity and in some biological properties. Mammalian reovirus is the prototype of the non-fusogenic orthoreoviruses and avian reovirus is the prototype of the fusogenic orthoreoviruses (Benavente & Martínez-Costas, 2007; Nibert & Schiff, 2001; Zhang et al., 2005) . They are non-enveloped viruses that contain a genome formed by ten dsRNA segments enclosed within a double protein-capsid shell. The reoviral genes are transcribed by a virionassociated RNA polymerase to generate mRNAs that are identical to the positive-sense strand of the dsRNA segments encoding them. Viral transcripts, which are designated with lower-case letters, possess a type-1 cap at their 59 ends and lack a polyadenylated 39 tail (Banerjee & Shatkin, 1970; Furuichi et al., 1975; Martinez-Costas et al., 1995) .
The replication and assembly of reoviruses takes place in distinctive cytoplasmic inclusions called viral factories (Fields et al., 1971) , which contain structural and non-structural viral proteins but lack membranes and cellular organelles.
The observation that the M3-encoded non-structural mNS protein of either MRV or ARV is the only viral protein that forms factory-like inclusions when expressed in transfected cells suggests that mNS forms the framework of the viral factories in infected cells (Becker et al., 2003; BrandarizNuñez et al., 2010; Broering et al., 2002; Tourís-Otero et al., 2004b) . Furthermore, it has been shown that viral core proteins and the non-structural protein sNS associate with mNS inclusions in co-transfected cells, thus suggesting that mNS recruits these proteins to the viral factories of infected cells (Miller et al., 2003 (Miller et al., , 2010 Tourís-Otero et al., 2004a) .
The M3 genes of MRV and ARV have been reported to express two protein isoforms in infected cells (Tourís-Otero et al., 2004b; Wiener et al., 1989) . The smaller isoforms could originate from post-translational cleavage or by secondary initiation at in-frame, downstream AUG codons of their respective m3 mRNAs. Compelling experimental evidence suggests that the smaller MRV mNS isoform is a primary translation product that originates by initiation at an internal AUG codon of the MRV m3 mRNA: (i) pulse-chase analysis of MRV-infected cells failed to demonstrate a precursorproduct relationship between the two MRV mNS isoforms (Wiener et al., 1989) ; (ii) two isoforms with electrophoretic mobilities similar to the ones produced in infected cells were synthesized by in vitro translation of the MRV m3 mRNA in reticulocyte lysates (Kobayashi et al., 2006; Wiener et al., 1989) ; (iii) the amino-termini of both MRV mNS and mNSC are blocked, thus suggesting that the two proteins are primary translation products (Wiener et al., 1989) ; and (iv) only mNSC is generated when the AUG codon closest to the 59 end of the MRV m3 mRNA is mutated (Arnold et al., 2008; Kobayashi et al., 2006) . If the smaller MRV mNS isoform originates from internally initiated translation, it would lack sequences from the amino terminus of mNS, and this has been experimentally demonstrated by subjecting the two MRV mNS isoforms to peptide mapping after N-chlorosuccinimide cleavage at tryptophan residues (Wiener et al., 1989) . Hence, the smaller MRV mNS isoform was designated mNSC to indicate that it originates from the carboxy terminus of mNS.
The electrophoretic mobilities of the two MRV mNS isoforms suggests that they have a molecular mass difference of 5 kDa; therefore MRV mNSC could be produced by initiating translation at the in-frame downstream AUG codons specifying methionines 41 or 57, since initiation at the next in-frame downstream AUG (specifying methionine 111) would generate a protein~12 kDa smaller than mNS (Fig. 1a) . The observation that only MRV mNS, but not mNSC, is synthesized by translation of an MRV m3 mRNA version containing a mutated AUG-41 codon (Arnold et al., 2008; Kobayashi et al., 2006) suggests that mNSC begins at methionine 41 of mNS. However, the possibility of starting translation at methionine 57 has not yet been explored.
In contrast with the MRV situation, the mechanism by which the smaller ARV mNS isoform is produced has not yet been addressed. In this study we investigated the mechanisms used by these viruses to generate their smaller mNS isoforms.
RESULTS
Two mNS isoforms are produced in ARV-and
MRV-infected cells
To identify the polypeptide isoforms expressed by the M3 genome segments of ARV and MRV, immunoprecipitation and immunoblot analysis of extracts from infected and uninfected cells were performed. The antiserum against MRV mNS immunoprecipitated several proteins from extracts of MRV-infected L929 cells (Fig. 2a, lane 4) , but only the 80 and 75 kDa polypeptides were recognized by the antiserum in a Western blot assay (Fig. 2a, lane 6 ), indicating that they are MRV mNS isoforms. Similarly, the antiserum against ARV mNS immunoprecipitated three proteins of 70, 55 and 35 kDa from extracts of ARVinfected chicken embryo fibroblasts (CEF) (Fig. 2b, lane 4) , but only the 70 and 55 kDa polypeptides were recognized by the antiserum in a Western blot assay (Fig. 2b, lane 6 ), indicating that they are ARV mNS isoforms. The 35 kDa protein is the viral non-structural protein sNS, which we have previously identified as a mNS-interacting protein (Tourís-Otero et al., 2004b) . Western blot analysis with anti-sNS antiserum confirmed the identity of this protein (result not shown).
It should be noted that whereas a molecular mass of 60 kDa has been described for the smaller ARV mNS isoform (Tourís-Otero et al., 2004b) , a closer examination of its electrophoretic mobility, by performing electrophoretic analysis with gradient and non-gradient gels containing different polyacrylamide concentrations and by using different MW markers, revealed that the smaller ARV mNS isoform migrates as a 55 kDa protein (data not shown). The expression of the two ARV mNS isoforms is not virus-strain or cell-type specific since the two isoforms were produced in: (i) CEF cells infected with the avian reoviruses S1133, 2408 and 173; and (ii) in avian CEF and DF-1 cells and mammalian Vero and HeLa cells infected with avian reovirus S1133 (data not shown).
The electrophoretic mobilities of the larger MRV and ARV mNS isoforms were those expected for the products where translation initiated at the AUG codons closest to the 59 end of their respective m3 mRNAs ( Fig. 1 ) and were coincident with the mobilities of the larger in vitro translation products of their respective m3 mRNAs (Fig.  3) . Therefore, these proteins were designated mNS to indicate that they are the non-structural m-class proteins encoded by the largest ORF of their respective M3 genes. The smaller MRV mNS isoform, but not its ARV counterpart, originates by initiation of translation at an internal AUG codon
Once it was confirmed that ARV and MRV express two mNS isoforms, the main thrust of the present study was to identify whether the smaller mNS isoforms originate by initiating translation at an internal in-frame AUG codon or by post-translational cleavage of precursor mNS. We first examined the possibility of internal initiation.
Examination of the nucleotide sequences of ARV and MRV m3 mRNAs revealed that the AUG codons closest to their 59 ends are in an optimal Kozak context (Kozak, 1991) , since the two of them have purine nucleotides in positions 23 and +4 (Fig. 1) . Consequently, these mRNAs should initiate translation exclusively at the AUG codons closest to their 59 ends and therefore should be monocistronic. However, compelling evidence (see Introduction) suggests that the smaller MRV mNS isoform is a primary translation product for which translation initiates at an internal AUG triplet of the MRV m3 mRNA. To assess whether the smaller ARV and MRV mNS isoforms are produced by secondary translation initiation, we followed two approaches. In the first approach, reticulocyte lysates were programmed with RNA isolated from both uninfected cells and reovirusinfected cells in the presence of [ 35 S]methionine. Reticulocyte lysates, as well as radioactive cytoplasmic extracts from infected and uninfected cells, were immunoprecipitated with the corresponding mNS antiserum, and the selected radioactive proteins were analysed by SDS-PAGE and autoradiography. The results revealed that while the two MRV mNS isoforms detected in infected cells (Fig. 3a , lane 6) were synthesized by in vitro translation of the MRV m3 mRNA (Fig. 3a, lane 4) , only the larger ARV mNS isoform, but not the 55 kDa isoform, was synthesized by in vitro translation of the ARV m3 mRNA (Fig. 3b , compare lanes 4 and 6). These results suggest that the smaller MRV mNS isoform, but not its ARV counterpart, is a primary translation product of the m3 mRNA.
As stated in the Introduction, the molecular mass difference between the two MRV mNS isoforms (~5 kDa) suggests that the smaller MRV isoform could originate by initiating translation at the in-frame downstream AUG codons specifying methionines 41 or 57 (Fig. 2a) . On the other hand, the predicted molecular mass difference between the two ARV isoforms is 15 kDa, implying that the smaller isoform might originate from initiating translation at methionines 127, 140 or 208 of ARV mNS (Fig. 1b) . The results shown in Fig. 3 (c) revealed that the smaller MRV mNS isoform has an electrophoretic mobility similar to that of in vitro-translated polypeptides that initiate translation at methionines 41 or 57 of MRV mNS, thus suggesting that this isoform could originate from initiating translation at one of these two AUG codons. It should be mentioned that the translated RNA in lane 1 of Fig. 3 (c) is a version of a MRV m3 mRNA that contains 13 extra nucleotides at its 59 end, and that synthesis of the 75 kDa isoform is barely detected following translation of this mRNA, suggesting that the AUG codon closest to the 59 end of the MRV m3 mRNA is not leaky when preceded by a longer 59 UTR. In contrast, the results shown in Fig. 3(d) indicate that the ARV mNS 55 kDa isoform migrates faster than the polypeptides for which translation initiates at methionines 127 and 140, but slower than the polypeptide for which translation initiates at methionine 208. These data indicate that the smaller MRV mNS isoform, but not its ARV counterpart, is a primary translation product of the m3 mRNA, and was therefore designated MRV mNSC to indicate that it originates from the C terminus of mNS.
The results presented so far did not allow us to assess whether MRV mNSC starts translation at methionine 41 or 57 of mNS. To clarify this point, we generated in vitrotranscribed MRV m3 mRNAs containing a type-1 cap and authentic 59 and 39 ends, either unmutated or containing single mutations (AUGAUUG) to change the methionines specified by codons 1, 41 and 57 to leucines. These RNAs were translated in reticulocyte lysates in the presence of [ 35 S]methionine, and the resulting radiolabelled proteins, as well as immunoprecipitated radiolabelled proteins from MRV-infected cells, were analysed by SDS-PAGE and autoradiography. The results shown in Fig. 3 (e) revealed that only mNSC is synthesized when AUG codon 1 is mutated (lane 3), and only mNS is produced when AUG codon 41 is mutated (lane 4). In contrast, the two mNS isoforms detected in infected cells (lane 1), as well as by in vitro translation of non-mutated m3 mRNA (lane 2), are similarly produced when AUG codon 57 is mutated (lane 5). Our finding that synthesis of mNSC is prevented by mutation of AUG codon 41, but not of AUG 57, indicates that mNSC originates from internal translation initiation at AUG codon 41 of MRV m3 mRNA. Synthesis of reovirus mNS isoforms two MRV mNS isoforms are already present in MRVinfected cells at the end of the radioactive pulse and that their relative intensities do not change significantly during the chase (Fig. 4a) . In contrast, the radioactive band corresponding to the smaller ARV mNS isoform was barely detectable at the end of the labelling pulse, but its intensity increased progressively with longer chase periods (Fig. 4b ).
These results demonstrate that the smaller ARV mNS isoform, but not its MRV counterpart, originates from post-translational cleavage.
If the 55 kDa ARV mNS isoform originates from a single mNS cleavage, a complementary 15 kDa polypeptide should be generated too. To detect the presence of this polypeptide in ARV-infected cells, cell extracts were immunoprecipitated with ARV-mNS-specific antiserum and the radioactive immunoprecipitated proteins were subsequently separated on an electrophoresis gel system (10 % tricine-SDS-PAGE gel) specifically designed to resolve small peptides (Schägger & von Jagow, 1987) . The autoradiogram, shown in Fig. 5(a) , revealed the presence of a radioactive polypeptide band of 17 kDa in immunoprecipitated extracts of ARV-infected cells (lane 4; marked with two asterisks) that did not show up in extracts from uninfected cells (lane 3). Furthermore, this polypeptide was recognized by ARV-mNS-specific antibodies in a Western blot assay of extracts from ARVinfected cells (Fig. 5b, lane 2) , but not from uninfected cells (Fig. 5b, lane 1) . These results indicate that the 17 kDa polypeptide is an ARV mNS isoform. To confirm this hypothesis, we performed a new pulse-chase analysis of ARV-infected cells, but the radioactive proteins were now resolved by the 10 % tricine-SDS-PAGE system. The autoradiogram, shown in Fig. 5(c) , revealed that, as with the 55 kDa mNS isoform, the 17 kDa polypeptide band was barely detectable at the end of the pulse period (lane 2), but its intensity gradually increased with longer chase periods (lanes 2-6). Furthermore, the increase in the intensity of both the 55 and 17 kDa bands was accompanied by a concomitant decrease in the intensity of the 70 kDa mNS protein band. Altogether, these results demonstrate that the 17 and 55 kDa polypeptides are ARV mNS isoforms that originate from a single post-translational cleavage of the 70 kDa ARV mNS precursor. It should be mentioned here that a faint 15 kDa band, which is recognized by anti-mNS antibodies, is also detected in infected cells (Fig. 5b, lane 2 and Fig. 5c , lane 6). We are now investigating whether this band corresponds to another ARV mNS isoform.
ARV mNS is cleaved near its amino terminus
To determine whether ARV mNS cleavage occurs near its amino-or carboxy-terminus, cytoplasmic extracts from both uninfected and ARV-infected CEF were incubated with mNS antiserum and the immunoprecipitated proteins were analysed by electrophoresis on a 10 % tricine-SDSpolyacrylamide gel. Visualization of the protein bands by Coomassie blue staining revealed the presence of a 17 kDa polypeptide in immunoprecipitated extracts from infected cells (Fig. 6 , lane 2, marked with two asterisks), which was not present in extracts from uninfected cells (Fig. 6, lane 1) . The fact that this polypeptide is recognized by ARV mNSspecific antibodies in an immunoblot assay (Fig. 6, lane 5) , indicates that it is an ARV mNS isoform. A slice containing the 17 kDa protein band was excised from the Coomassiestained gel, digested with trypsin and subjected to mass spectrometric analysis. The analysis revealed that this polypeptide contained two tryptic fragments whose amino acid sequences matched the regions containing residues 24-45 and 91-99 of the deduced ARV mNS amino acid sequence. These results demonstrate that the 17 kDa polypeptide is located at the amino terminus of mNS and hence it was designated mNSN. Conversely, the complementary 55 kDa isoform was termed mNSC.
Finally, we wanted to identify the ARV mNS cleavage site by subjecting gel-purified mNSC to Edman degradation analysis, but unfortunately mNSC could not be purified from the SDS-PAGE gel because it co-migrated in the gel with the immunoglobulin heavy chain (Fig. 6 , lane 5).
DISCUSSION
Viruses use a variety of strategies to maximize protein expression from limited-size genomes; the most common ones are alternative translation initiation from polycistronic transcripts and proteolysis of primary translation products. In this report we provide evidence that two species groups of the genus Orthoreovirus use different strategies to generate their smaller mNS isoforms. Thus, MRV mNSC is produced by initiating translation at the internal AUG-41 codon of the MRV m3 mRNA, whereas ARV mNSC is generated by a single post-translational cleavage of the precursor mNS. In spite of being generated by completely different mechanisms, the two mNSC proteins lack sequences from the amino terminus of their respective precursors. These observations, and the facts that the initiator MRV mNSC AUG codon is conserved 4) and ARVinfected (lanes 2 and 5) CEF cells were lysed in radioimmunoprecipitation buffer at 12 h p.i. The extracts were incubated with antiserum against ARV mNS protein and immune complexes, as well as protein molecular weight markers (lane 3), were loaded onto two tricine-SDS-PAGE gels (10% acrylamide). Protein bands in one gel were visualized by staining with Coomassie brilliant blue G250 (lanes 1-3) , and the proteins in the other gel were subjected to Western blot analysis (lanes 4 and 5). A slice containing the 17 kDa Coomassie-stained band (marked **, lane 2) was excised from the gel for mass spectrometric analysis. The molecular masses of the protein markers are indicated between the two panels, and the positions of the immunoglobulin heavy (HC) and light (LC) chains, as well as the position of the 17 kDa ARV mNS isoform (**), are indicated on the right. among all sequenced MRV M3 genes and that ARV mNSC is generated in cells infected with three different ARV isolates, suggest that mNSC may be important for reovirus replication. However, recent reports reveal that although MRV mNSC is still able to form inclusions, it is incapable of restoring MRV growth in cultured cells when mNS is absent (Arnold et al., 2008; Kobayashi et al., 2006 Kobayashi et al., , 2009 . These observations suggest both that inclusion formation is an important, though not a sufficient, function of mNS during MRV reovirus replication, and that key functions for viral growth are localized within those amino-terminal sequences of MRV mNS that are missing in mNSC. These sequences have already been shown to be required for association with, and inclusion recruitment of, MRV proteins m2 and sNS (Broering et al., 2002; Miller et al., 2003 Miller et al., , 2010 . We have similarly found that sequences contained within mNSN are necessary for association of ARV mNS with several structural and non-structural proteins (unpublished data). Although not strictly required for factory formation and viral growth on cultured cells, mNSC proteins might be important for reovirus replication and/or spread within host organisms, as suggested by Kobayashi et al. (2009) The results reported by different laboratories strongly suggest that MRV mNSC originates by starting translation at an internal in-frame AUG codon of the MRV m3 mRNA. Our data confirmed this suggestion and further demonstrated that the starting codon for MRV mNSC synthesis is the one specifying Met-41 of MRV mNS, but not the one specifying Met-57. Ribosomes could initiate translation at codon 41 by either of two mechanisms: capindependent internal entry and cap-dependent leaky scanning (Jackson, 2005; Sonenberg & Hinnebusch, 2009) . Our finding that the synthesis of MRV mNSC is greatly increased upon mutation of the AUG closest to the 59 end of the MRV m3 mRNA indicates that 40S ribosomal subunits start translation at codon 41 after scanning past the first AUG codon, and not by direct internal entry. At least two other reoviral proteins, MRV s1S and ARV p17, have been reported to initiate translation from internal cistrons by a leaky scanning mechanism (Ernst & Shatkin, 1985; Racine et al., 2007) . In both cases leaky scanning appears to be facilitated by the suboptimal context of the 59-proximal AUG triplet of their respective mRNAs. However, the optimal context of the AUG codon closest to the 59 end of the MRV m3 mRNA (Fig. 1a) should dramatically reduce or abolish translation initiation from downstream AUG codon 41 and hence MRV mNSC synthesis. There are some reported examples of leaky scanning despite the presence of a 59-proximal AUG codon in a good Kozak-sequence context. This usually happens when the 59 UTR is too short for the first AUG triplet to be efficiently recognized (Kozak, 1991; Ruan et al., 1994; Sedman et al., 1990; Spiropoulou & Nichol, 1993) . Two observations suggest that the ability of small ribosomal subunits to scan past the optimal 59-proximal AUG of the MRV m3 mRNA can be attributed to the small size of its 59 UTR (18 nt; Fig. 1a ): (i) synthesis of MRV mNSC is drastically reduced when reticulocytes are programmed with an m3 mRNA version that contains 13 extra nucleotides at its 59 UTR (Fig. 3c, lane 1) ; and (ii) the optimal 59-proximal AUG codon of the MRV m3 mRNA is leaky, whereas the one of its ARV counterpart, which contains a 6 nt-longer 59 UTR, is not.
In contrast with the situation for MRV, the results of this study demonstrate that ARV mNSC originates from a single post-translational cleavage event, which occurs near the amino terminus of mNS. This cleavage, which occurs with 30 % efficiency, also generates a complementary Nterminal polypeptide of~17 kDa. Thus, the ARV M3 gene expresses three protein isoforms, whereas only two are expressed by its MRV counterpart. Similarly to mNS, the ARV structural proteins mB and sA have been shown to be partially cleaved near their amino termini to generate small amino-terminal peptides (mBN and sAN, respectively) and larger carboxy-terminal proteins (mBC and sAC, respectively) (Ji et al., 2010; Varela et al., 1996) . Altogether, these results allow us to expand the protein repertoire known to be expressed by ARV to 18 polypeptides, 12 of which are primary translation products and six of which are nonstructural proteins (Table 1) .
Recent results from our laboratory indicate that ARV mNS cleavage is much less efficient in uninfected than in infected cells, suggesting that the protease involved is either a viral protein or a cellular protein whose activity is triggered by the viral infection. Experiments are in progress in our laboratory to identify the ARV mNS cleavage site and the mechanism involved in processing mNS.
METHODS
Cells, viruses and antibodies. Preparation of primary cultures of CEFs, and conditions for growing ARVs in CEFs and the MRV strain type 3 Dearing in monolayers of mouse L929 fibroblasts have been described previously (Grande & Benavente, 2000; Nibert & Fields, 1992) . Rabbit polyclonal serum against ARV S1133 mNS protein was raised in our laboratory (Tourís-Otero, et al., 2004b) , and rabbit polyclonal serum against MRV type 3 mNS protein was kindly provided by Dr Terence Dermody (Kobayashi, et al., 2009) . Peroxidaseconjugated goat anti-rabbit antibody was purchased from Sigma.
Viral infection, metabolic radiolabelling, cell fractionation, immunoassays and protein analysis. Infection of cultured cells, metabolic radiolabelling, immunoprecipitation and immunoblotting were performed as previously described (Martinez-Costas et al., 1995; Tourís-Otero et al., 2004b; Varela et al., 1996) . Proteins were analysed by SDS-PAGE (10 % acrylamide) on discontinuous gels (Laemmli, 1970) . The tricine-SDS-PAGE system described by Schägger & von Jagow (1987) was used when trying to resolve low-molecular-mass proteins. For visualization of the radioactive protein bands, the gels were dried and exposed to X-ray film (Agfa-Curix AFW).
For pulse-chase analysis, mock-infected and reovirus-infected cells were incubated for 2 h at 12 h p.i. in medium lacking methionine and cysteine, and then incubated for 10 min in the same medium supplemented with 500 mCi [
S]amino acids (methionine and cysteine) ml

21
. The cells were chased for the indicated times in non-radioactive medium supplemented with an excess of nonradiolabelled methionine and cysteine, and then lysed. The resulting cell extracts were immunoprecipitated with the corresponding antimNS antiserum and then analysed by SDS-PAGE (10 % acrylamide) and autoradiography.
Plasmid construction. The construction of recombinant plasmids expressing full-length and amino-terminal truncations of ARV mNS have been described (Brandariz-Nuñez et al., 2010) . To generate a DNA insert encoding MRV mNS, total RNA isolated from MRV-infected L929 cells was amplified by RT-PCR using the forward primer 59-GCTTCC-CATATTCCGCTCGAGGCTAAAGTGACCGTGGTCATG-39 and the reverse primer: 59-GCTAAAGGAAAATTGCGGCCGCTGATGAAT-GGGGGTCG-39. The PCR product was digested with XhoI and NotI (Promega) and inserted into the XhoI and NotI sites of the pCINeo plasmid (Promega) to generate the recombinant plasmid pCINeoMRVmuNS.
To express amino-terminally truncated versions of the MRV mNS protein, the insert contained within pCINeo-MRVmuNS was amplified by PCR. To generate Reo3muNS D40, the forward primer used was 59-GCTTCCATATTCCGCTCGAGATGTCAATCGC-39 and the reverse primer used was 59-GCTAAAGGAAAATTGCGGCCGCT-GATGAATGGGGGTCG-39. To generate Reo3muNS D56, the forward primer used was 59-GCTTCCATATTCCGCTCGAGATGTCT-ATACCTTATCAG-39 and the reverse primer used was 59-GCT-AAAGGAAAATTGCGGCCGCTGATGAATGGGGGTCG-39. The amplified products were digested with XhoI and NotI and cloned into the XhoI and NotI sites of the pCINeo vector.
To generate templates that express MRV m3 mRNAs possessing the correct 59 and 39 termini, M3 sequences contained within the pCINeoMRVmuNS plasmid were amplified by PCR using the forward primer 59-TAATACGACTCACTATAGGGCTAAAGTGACCGTGGTC-39 and the reverse primer 59-GATGAATGGGGGTCGGGAAG-39, in order to juxtapose the T7 promoter and the +1 nt of the MRV M3 gene. These primers were also used to amplify the mutated versions of the MRV M3 gene shown below.
To mutate the MRV m3 AUG codons 1 (M1L), 41 (M41L) and 57 (M57L), we used a QuikChange site-directed mutagenesis kit (Stratagene), according to the manufacturer's specifications, by using pCIneo Reo3muNS-UTR as template. To mutate AUG codon 1 the forward primer was 59-GTGACCGTGGTCTTGGCTTCATTCAAG-GGATTC-39 and the reverse primer was 59-GAATCCCTTGAATGAA-GCCAAGACCACGGTCAC-39. To mutate AUG codon 41 the forward primer was 59-ACTCCGTCTGTGGATTTGTCTCAATCGCGTG-39 and the reverse primer was 59-CACGCGATTGAGACAAATCCACACAG-ACGGAGT-39. To mutate AUG codon 57 the forward primer was 59-AATTGAGCAAGGGTCCTTGTCTATACCTTATCA-39 and the reverse primer was 59-TGATAAGGTATAGACAAGGACCCTTGCTCAATT-39. In all cases, a methionine-specifying AUG codon was replaced by a leucine-specifying UUG codon. The correctness of all recombinant plasmids was confirmed by nucleotide sequencing.
In vitro transcription and translation. The recombinant plasmids used as templates were linearized with NotI, purified by extraction with phenol/chloroform, precipitated with ethanol and resuspended in sterile water at a final concentration of 1 mg ml
. In vitro transcription from the T7 promoter was performed by using a RiboMAX Large Scale RNA Production System (Promega), and 59-capped RNA transcripts were synthesized by supplementing the transcription reaction mixtures with Ribo m7G Cap Analogue (Promega) according to the manufacturer's specifications. The resulting RNAs were precipitated by the addition of one volume of 5 M ammonium acetate and were then washed in 70 % ethanol, dried and resuspended in water. Transcription of the linearized pCINeoMRVmuNS plasmid generated an MRV m3 mRNA version containing 13 extra nucleotides (from the pCINeo multiple cloning site) at the 59 end.
In vitro translation was carried out by using a Rabbit Reticulocyte Lysate System (nuclease-treated; Promega) following the manufacturer's instructions, for 90 min at 30 uC in the presence of 50 mg RNA ml 21 and 0.4 mCi [
S]methionine ml 21 (Hartmann analytic KSM-01).
Isolation and mass spectrometric analysis of the 17 kDa ARV mNS isoform. Approximately 10610 7 avian reovirus-infected CEF cells (10 p.f.u. per cell) were harvested at 18 h p.i. The cells were washed twice with PBS (pH 7.2) and then lysed by incubation for 30 min on ice with lysis buffer [10 mM Pipes, pH 6.8, 3 mM MgCl 2 , 100 mM KCl, 300 mM sucrose, 1 % Triton X-100 and protease inhibitors (Roche)]. The lysate was centrifuged at 16 500 g for 10 min at 4 uC, and the resulting supernatant was immunoprecipitated with ARV-mNS-specific antiserum. Immune complexes were resolved on a tricine-SDS-PAGE gel (10 % acrylamide) (Schägger & von Jagow, 1987) and protein bands were visualized by staining with Coomassie brilliant blue G250. A slice containing the 17 kDa polypeptide band was excised from the gel, washed sequentially with 50 mM ammonium bicarbonate and acetonitrile, and then incubated for 8 h at 37 uC with 12.5 mg trypsin ml 21 (Gibco) in 50 mM ammonium bicarbonate. Tryptic peptides were extracted by the addition of 70 % acetonitrile containing 0.5 % trifluoroacetic acid (TFA); the eluted peptides were dried by speed-vacuum centrifugation and finally resuspended in 4 ml of 30 % acetonitrile and 0.1 % TFA. A 0.5 ml aliquot of the mixture was added onto a matrix consisting of 0.5 ml of 5 mg 2,5-dihydroxybenzoic acid ml 21 in water/acetonitrile (2 : 1) containing 0.1 % TFA. Samples were measured on a 4800 MALDI-TOF-TOF Analyser (Applied Biosystems/MSD SCIEX) in positive ion reflector mode. Internal calibration of MALDI-TOF mass spectra was performed by using two trypsin autolysis ions with mass : charge ratios (m/z) of 842.510 and 2211.105; for MALDI-MS/MS, calibrations were performed with fragment ion spectra obtained for the proton adducts of a peptide mixture covering the m/z 800-3200 region. Proteins were identified by peptide mass fingerprinting and further MS/MS analysis for peptide sequencing. Following MALDI-TOF-TOF, the instrument was switched to MS/MS mode, and the five strongest peptides from the MS scan were isolated and fragmented by collision-induced dissociation with air. The ion acceleration voltage was 20 kV. The MALDI-MS data obtained were processed further by using the GPS Explorer software (Applied Biosystems) and using MASCOT to search against the Swiss-Prot database.
